The European Medicines Agency's Committee for Medicinal Products for Human Use yesterday posted its agenda for the upcoming week of regulatory workflow, Citi analyst Yigal Nochomovitz tells investors in a research note. Included are oral explanations on February 20 for both Portola Pharmaceuticals' AndexXa and Bevyxxa. It also seems like the CHMP could render a formal opinion on AndexXa today, and for Bevyxxa in March, Nochomovitz writes. The analyst notes that while the apparent timing of the oral hearing and formal opinion for AndexXa on the same day is unusual, his initial read is that this is a positive. He keeps a Buy rating on Portola shares with a $78 price target.